Loading asset research
AbCellera Biologics Inc. Common Shares
ABCLNasdaq · USD · StocksQuote as of · Exchange session not verified$10.90
+4.16%
Today
ABCL
Loading 1D prices…
Market cap
$3.5B
Volume
4.4M
52w high
$12.5852w low
$2.74Company profile
AbCellera Biologics Inc. Common Shares
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Vancouver, BC, United States
Employees
562
Fiscal year end
1231
CIK
1703057
Session & valuation
Open$10.55
Previous close$10.46
Day high$10.95
Day low$10.32
30-day avg. volume8.2M
Outstanding shares306.6M
Diluted EPS-$0.49
Latest annual period
P/E (trailing)-22.23
P/E (forward)-15.23
Price / book3.72
Beta1.32
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| AMLXAmylyx Pharmaceuticals Inc. Common Stock | $3.5B | $0.00 | — | -$1.53 | -1.46% | Buy |
| OGNOrganon & Co. Common Stock | $3.6B | $6.2B | +3.01% | $0.72 | +0.11% | Sell |
| LEGNLegend Biotech Corporation American Depositary Shares | $3.6B | $1B | -28.85% | -$1.62 | -2.89% | Buy |
| IDYAIDEAYA Biosciences Inc. Common Stock | $3.6B | $218.7M | -51.99% | -$1.28 | +0.32% | Buy |
| DYNDyne Therapeutics Inc. Common Stock | $3.4B | $0.00 | — | -$3.47 | -1.03% | Buy |